Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies.
about
Neuropsychological rehabilitation for multiple sclerosisInterferon beta for secondary progressive multiple sclerosisNeuropsychological rehabilitation for multiple sclerosisNeuropsychological rehabilitation for multiple sclerosisInterferon beta for secondary progressive multiple sclerosisNeurobehavioral burden of multiple sclerosis with nanotheranosticsClinical correlates of grey matter pathology in multiple sclerosisTreatment of cognitive impairment in patients with multiple sclerosisPsychopathology in multiple sclerosis: diagnosis, prevalence and treatmentImpact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational studyManaging Neuropsychological Impairment in Multiple Sclerosis: Pilot Study on a Standardized Metacognitive Intervention.Grey matter lesions in MS: from histology to clinical implications.Gray matters in multiple sclerosis: cognitive impairment and structural MRI.Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) studyA Cochran-Armitage-type and a score-free global test for multivariate ordinal data.Relevance of quality of life assessment for multiple sclerosis patients with memory impairmentLongitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years.Cognitive changes in multiple sclerosis.The size of the treatment effect: do patients and proxies agree?Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKOREA putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis.Cognitive function and quality of life in multiple sclerosis patients: a cross-sectional studyCortical pathology and cognitive impairment in multiple sclerosis.Risk factors for and management of cognitive dysfunction in multiple sclerosis.Youth and environmental enrichment generate serum exosomes containing miR-219 that promote CNS myelination.Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis.Is the concept of quality of life relevant for multiple sclerosis patients with cognitive impairment? Preliminary results of a cross-sectional studyPatient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV studyPerceived cognitive decline in multiple sclerosis impacts quality of life independently of depression.Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study.Evolving expectations around early management of multiple sclerosis.Only low frequency event-related EEG activity is compromised in multiple sclerosis: insights from an independent component clustering analysis.Cognitive impairment and "invisible symptoms" are not associated with CCSVI in MS.Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional studyApathy/depression, but not subjective fatigue, is related with cognitive dysfunction in patients with multiple sclerosis.Quantification of relevance of quality of life assessment for patients with cognitive impairment: the suitability indices.A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity
P2860
Q24200424-7417A239-F02C-4CB5-B07F-F7D3BF0799A4Q24203879-A3AD565A-904B-4A55-B9BC-D3B3A36F6ABFQ24234991-9EBB8833-7F08-42E3-91A4-8B3198C0DFCCQ24235230-48E7867A-29FA-409A-A84B-F84597F03B6DQ24240509-541B404F-32E4-4C41-87C8-570FB768F8FEQ26778311-C9300E84-618F-4C56-BFFD-BCD663B46ACAQ26999302-838FAE9B-82E3-4477-85B5-B84ABB221451Q28272736-B57EB49A-723D-4495-B99B-C2E7579E52DFQ28301691-F69F9C2A-07A0-406C-8DCC-0C52EF9F63F9Q28730321-17580C95-6268-453C-B72C-3F06B3322FAAQ30409871-3BF68C1D-E1B7-43B7-A267-A687BF9594C2Q30574566-73FD5005-645E-4D2C-BAE6-093E4A3FA632Q30768942-337B1B12-5682-4AEA-912E-CC3EF3340A61Q31038347-A96977D0-87C0-42C4-B0C0-B15E4FAFCA1EQ31049899-727B0A3A-D254-4490-9C16-C5C36D964876Q31108979-751A36FB-C3E3-4E3C-A833-0DBF43C93B19Q33321691-D48F6FB3-8EF6-4D32-8D38-5E6B9AA52902Q33377548-D5855EE6-E0C7-4ACE-9F2E-773FA9E6E7A7Q33421586-0141AAB5-F064-4283-A2F8-091B434D365CQ33520391-C03D19D3-D4DB-480A-A3FB-FA3989F4E4AFQ33573208-2ED7ED95-42ED-4EB0-BEE3-2C9491F5C011Q33589940-5890130B-D3F4-4C10-BD3A-61A354145403Q33769940-47D45867-938F-4DE9-BDD3-117D8B6464C9Q33810669-47081B91-3732-4A3F-B585-E7F5C50E2E11Q33837296-743B7030-3424-418C-AA6C-3CECFAC528EBQ33893669-AE88D8EE-3ED2-4685-9073-96CF116DD05EQ33894302-3FE57C3D-AD55-4F5E-B3E6-B6C2B571DE21Q34102803-929D7123-11E2-4317-8EA3-036B699937A2Q34146255-8730F6BD-B1E0-4F35-ABCC-41F9B4385FCAQ34184837-9BBD763E-8AF4-4533-B74C-411773125730Q34196199-58685983-3986-474F-9EBF-665FD9296481Q34338582-334C2F20-F581-4B70-B105-B9F4ADC8AF63Q34409346-73FE29F1-2100-4668-8BDE-25EC30DC1EC0Q34409412-E4FF6D73-0964-43C1-BD7B-2883E216375DQ34429314-DF42961A-2A5F-4AB3-BB32-3EFF68156496Q34868382-7236135C-4D6C-4DB8-887C-3F517922E310Q34926430-234637B7-0E06-4C24-8B3D-C385FF5413EDQ35083857-237914AD-F3D0-4582-9F99-1DFB59806F48Q35141174-857136F2-874F-4B13-A7E1-52F9852CC205Q35215662-5F167F0D-9D0F-4A35-A76B-2AD513A1D23F
P2860
Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Multiple sclerosis-related cog ...... onal and longitudinal studies.
@ast
Multiple sclerosis-related cog ...... onal and longitudinal studies.
@en
type
label
Multiple sclerosis-related cog ...... onal and longitudinal studies.
@ast
Multiple sclerosis-related cog ...... onal and longitudinal studies.
@en
prefLabel
Multiple sclerosis-related cog ...... onal and longitudinal studies.
@ast
Multiple sclerosis-related cog ...... onal and longitudinal studies.
@en
P1476
Multiple sclerosis-related cog ...... ional and longitudinal studies
@en
P2093
Emilio Portaccio
Valentina Zipoli
P356
10.1016/J.JNS.2005.08.019
P577
2006-04-27T00:00:00Z